Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate DDI with Rifampicin and Cyclosporine
NCT07196449Phase 1Active, not recruiting
- Sponsor
- Seoul National University Bundang Hospital
- Start
- May 2025
- Primary completion
- Jun 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of methotrexate in rheumatoid arthritis (RA), psoriasis and cancer (6 arms), sponsored by Seoul National University Bundang Hospital. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to Last Measurable Concentration. Started May 2025; status: active, not recruiting.
02
Drugs
methotrexate
03
Conditions
rheumatoid arthritis (RA)psoriasiscancer
Beyond the preview
Go deeper on NCT07196449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07196449.